Patents Assigned to REATA PHARMACEUTICALS
  • Publication number: 20240335457
    Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolon.
    Type: Application
    Filed: February 26, 2024
    Publication date: October 10, 2024
    Applicant: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Colin J. MEYER, Warren HUFF
  • Publication number: 20240317676
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Application
    Filed: February 6, 2024
    Publication date: September 26, 2024
    Applicant: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Eric ANDERSON, Xin JIANG, Melean VISNICK
  • Publication number: 20240293351
    Abstract: Provided are methods of administering synthetic tri terpenoids, such as bardoxolone methyl or omaveloxolone, to a patient in need thereof while avoiding adverse drug interactions with cytochrome P450 3A4 (CYP3A4) modulators. Such treatment methods comprise avoiding, contraindicating, or discontinuing concomitant use or co-administration of a cytochrome P450 3A4 modulator.
    Type: Application
    Filed: December 10, 2021
    Publication date: September 5, 2024
    Applicant: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Scott Aaron REISMAN, Sarabjit GAHIR
  • Patent number: 12065464
    Abstract: The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.
    Type: Grant
    Filed: June 25, 2021
    Date of Patent: August 20, 2024
    Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Eric Anderson, Xiaofeng Liu, Andrea Decker
  • Patent number: 12060340
    Abstract: Provided herein are compounds, compositions and methods for treating and preventing diseases and disorders, comprising administering to patients therapeutically effective amounts of cysteine-dependent inverse agonists of the nuclear receptor ROR?/ROR?t. In some such embodiments, the inverse agonists bind to cysteine 476 of a nuclear receptor ROR? in the patient. Also provided are methods, as well as compounds and compositions, for modulating the activity of ROR? and ROR?t by binding to the allosteric binding site through a covalent bond. In some aspects, the present disclosure relates to using compounds containing Michael acceptor groups which bind to a cysteine residue in the allosteric binding site such as cysteine 476 in ROR?.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: August 13, 2024
    Assignee: REATA PHARMACEUTICALS, INC
    Inventors: Melean Visnick, Xin Jiang
  • Publication number: 20240228528
    Abstract: The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.
    Type: Application
    Filed: January 12, 2024
    Publication date: July 11, 2024
    Applicant: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Ahmad Y. SHEIKH, Alessandra MATTEI, Xiu C. WANG
  • Publication number: 20240182507
    Abstract: Provided herein are biaryl amides and coumarin-based compounds with modified sugar groups having the formulas: wherein variables are as defined herein. Pharmaceutical compositions of the compounds are also provided.
    Type: Application
    Filed: October 12, 2023
    Publication date: June 6, 2024
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Xin JIANG, Melean VISNICK, Christopher F. BENDER, Gary BOLTON, Bradley CAPRATHE, Chitase LEE
  • Patent number: 11993574
    Abstract: Disclosed herein are compounds of the formula: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to modulate the activity of IL-17 and ROR?. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or for autoimmune disorders.
    Type: Grant
    Filed: June 17, 2019
    Date of Patent: May 28, 2024
    Assignee: REATA PHARMACEUTICALS, INC
    Inventors: Xin Jiang, Melean Visnick, Christopher F. Bender, Gary Bolton, Bradley Caprathe, Chitase Lee, Brian Kornberg, Patrick O'Brien, Martha R. Hotema
  • Patent number: 11919838
    Abstract: This invention provides, but is not limited to, novel oleanolic acid derivatives having the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds, methods and intermediates useful for making the compounds, and methods of using the compounds and compositions.
    Type: Grant
    Filed: July 9, 2021
    Date of Patent: March 5, 2024
    Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Eric Anderson, Xin Jiang, Melean Visnick
  • Patent number: 11911395
    Abstract: The present invention relates to methods of treating and/or preventing obesity comprising the administration of antioxidant inflammation modulators described herein, including for example bardoxolone methyl.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: February 27, 2024
    Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Colin J. Meyer, Warren Huff
  • Patent number: 11873320
    Abstract: The present invention relates generally to the compound: N-((4aS,6aR,6bS,8aR,12aS,14aR,14bS)-11-cyano-2,2,6a,6b,9,9,12a-heptamethyl-10,14-dioxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,12a,14,14a,14b-octadecahydropicen-4a-yl)-2,2-difluoropropanamide, polymorphic forms thereof, methods for preparation and use thereof, pharmaceutical compositions thereof, and kits and articles of manufacture thereof.
    Type: Grant
    Filed: August 6, 2021
    Date of Patent: January 16, 2024
    Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Ahmad Y. Sheikh, Alessandra Mattei, Xiu C. Wang
  • Patent number: 11827664
    Abstract: Provided are biaryl amides and coumarin-based compounds with modified sugar groups for treatment of diseases associated with heat shock protein pathway. The compounds having the following formulas, wherein variables are as defined herein. Formulae (I), (II), (III), (IV), and (V), Pharmaceutical compositions of the compounds are also provided. These biaryl amides and coumarin-based derivatives with modified sugar groups are useful for treatment and prevention of diseases and disorders, including neurological disorders, such as neurodegenerative diseases and nerve damaging disorders, for example, diabetic peripheral neuropathy.
    Type: Grant
    Filed: May 14, 2019
    Date of Patent: November 28, 2023
    Assignee: REATA PHARMACEUTICALS, INC
    Inventors: Xin Jiang, Melean Visnick, Christopher F. Bender, Gary Bolton, Bradley Caprathe, Chitase Lee
  • Patent number: 11814338
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Grant
    Filed: December 6, 2021
    Date of Patent: November 14, 2023
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
  • Publication number: 20230255982
    Abstract: The present invention provides methods of treating patients infected with a coronavirus. In particular, provided are methods of treating or preventing COVID-19, or symptoms or complications thereof, in patients in need thereof using bardoxolone methyl or analogs thereof, and/or preventing the onset of COVID-19 in patients infected with SARS-COV-2.
    Type: Application
    Filed: May 7, 2021
    Publication date: August 17, 2023
    Applicant: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventors: Deborah FERGUSON, W. Christian WIGLEY, Colin MEYER, J. Warren HUFF, Robert M. KRAL, Jr.
  • Patent number: 11584775
    Abstract: Disclosed herein are C4 modified oleanolic acid derivatives of the formula: Formula (X) or Formula (XII), as well as analogs thereof, wherein the variables are defined herein. In addition, disclosed herein are pharmaceutical compositions of these derivatives or analogs, methods for their manufacture, and methods for their use, including for the prevention and treatment of diseases or disorders associated with overproduction of IL-17.
    Type: Grant
    Filed: September 23, 2016
    Date of Patent: February 21, 2023
    Assignee: REATA PHARMACEUTICALS, Inc.
    Inventors: Melean Visnick, Xin Jiang, Martha R. Hotema, Chitase Lee, Bradley William Caprathe, William H. Roark, Gary L. Bolton
  • Patent number: 11446313
    Abstract: The present invention provides methods of treating or preventing Alport syndrome in a patients in need thereof using bardoxolone methyl or analogs thereof, and/or improving the kidney function of patients who have been diagnosed with Alport syndrome.
    Type: Grant
    Filed: February 11, 2021
    Date of Patent: September 20, 2022
    Assignee: REATA PHARMACEUTICALS HOLDINGS, LLC
    Inventor: Colin J. Meyer
  • Publication number: 20220281807
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Application
    Filed: December 6, 2021
    Publication date: September 8, 2022
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Eric ANDERSON, Gary L. BOLTON, Bradley CAPRATHE, Xin JIANG, Chitase LEE, William H. ROARK, Melean VISNICK
  • Patent number: 11406648
    Abstract: Disclosed herein are novel C17-heteroaryl derivatives of oleanolic acid, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds, for example, as antioxidant inflammation modulators, and compositions thereof are also provided.
    Type: Grant
    Filed: December 28, 2020
    Date of Patent: August 9, 2022
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Xin Jiang, Christopher F. Bender, Melean Visnick
  • Patent number: 11401294
    Abstract: Disclosed are co-crystal forms of N-(2-(5-(((2R,3R,4S,5R)-3,4-dihydroxy-5-methoxy-6,6-dimethyltetra-hydro-2H-pyran-2-yl)oxy)-3?-fluoro-[1,1?-biphenyl]-2-yl)ethyl)-acetamide and L-proline or D-proline, their pharmaceutical compositions, processes of manufacture, and methods of use for treating neurodegenerative disorders such as diabetic peripheral neuropathy.
    Type: Grant
    Filed: June 5, 2020
    Date of Patent: August 2, 2022
    Assignee: Reata Pharmaceuticals, Inc.
    Inventors: Xin Jiang, John Allen Walling, Melanie J. Bevill, Christopher S. Seadeek, Jared P. Smit
  • Publication number: 20220135534
    Abstract: Disclosed herein are compounds of the formulas: as well as analogs thereof, wherein the variables are defined herein. Also provided are pharmaceutical compositions thereof. In some aspects, the compounds and compositions provided herein may be used to inhibit ROR? and/or reduce the expression of IL-17. Also provided are methods of administering compounds and composition provided herein to a patient in need thereof, for example, for the treatment or prevention of diseases or disorders associated with inflammation or autoimmune disorders.
    Type: Application
    Filed: January 18, 2022
    Publication date: May 5, 2022
    Applicant: REATA PHARMACEUTICALS, INC.
    Inventors: Xin JIANG, Christopher F. BENDER, Melean VISNICK, Martha R. HOTEMA, Zachary S. SHELDON, Chitase LEE, Bradley William CAPRATHE, Gary BOLTON, Brian KORNBERG